Display options
Cite
Mewton N, Roubille F, Bresson D, et al. Effect of Colchicine on Myocardial Injury in Acute Myocardial Infarction. Circulation. 2021;144(11):859-869doi: 10.1161/CIRCULATIONAHA.121.056177.
Mewton, N., Roubille, F., Bresson, D., Prieur, C., Bouleti, C., Bochaton, T., Ivanes, F., Dubreuil, O., Biere, L., Hayek, A., Derimay, F., Akodad, M., Alos, B., Haider, L., El Jonhy, N., Daw, R., De Bourguignon, C., Dhelens, C., Finet, G., Bonnefoy-Cudraz, E., Bidaux, G., Boutitie, F., Maucort-Boulch, D., Croisille, P., Rioufol, G., Prunier, F., & Angoulvant, D. (2021). Effect of Colchicine on Myocardial Injury in Acute Myocardial Infarction. Circulation, 144(11), 859-869. https://doi.org/10.1161/CIRCULATIONAHA.121.056177
Mewton, Nathan, et al. "Effect of Colchicine on Myocardial Injury in Acute Myocardial Infarction." Circulation vol. 144,11 (2021): 859-869. doi: https://doi.org/10.1161/CIRCULATIONAHA.121.056177
Mewton N, Roubille F, Bresson D, Prieur C, Bouleti C, Bochaton T, Ivanes F, Dubreuil O, Biere L, Hayek A, Derimay F, Akodad M, Alos B, Haider L, El Jonhy N, Daw R, De Bourguignon C, Dhelens C, Finet G, Bonnefoy-Cudraz E, Bidaux G, Boutitie F, Maucort-Boulch D, Croisille P, Rioufol G, Prunier F, Angoulvant D. Effect of Colchicine on Myocardial Injury in Acute Myocardial Infarction. Circulation. 2021 Sep 14;144(11):859-869. doi: 10.1161/CIRCULATIONAHA.121.056177. Epub 2021 Aug 23. PMID: 34420373; PMCID: PMC8462445.
Copy Download .nbib Format: NLM
Share it on

Circulation. 2021 Sep 14;144(11):859-869. doi: 10.1161/CIRCULATIONAHA.121.056177. Epub 2021 Aug 23.

Effect of Colchicine on Myocardial Injury in Acute Myocardial Infarction.

Circulation

Nathan Mewton, François Roubille, Didier Bresson, Cyril Prieur, Claire Bouleti, Thomas Bochaton, Fabrice Ivanes, Olivier Dubreuil, Loïc Biere, Ahmad Hayek, François Derimay, Mariama Akodad, Benjamin Alos, Lamis Haider, Naoual El Jonhy, Rachel Daw, Charles De Bourguignon, Carole Dhelens, Gérard Finet, Eric Bonnefoy-Cudraz, Gabriel Bidaux, Florent Boutitie, Delphine Maucort-Boulch, Pierre Croisille, Gilles Rioufol, Fabrice Prunier, Denis Angoulvant

Affiliations

  1. Hôpital Cardiovasculaire Louis Pradel, Clinical Investigation Center, INSERM 1407 and INSERM CarMeN 1060, Hospices Civils de Lyon and Claude Bernard University, Lyon, France (N.M., C.P., T.B., A.H., F.D., L.H., N.E.J, R.D., C.D.B., G.F., E.B.-C., G.R.).
  2. PhyMedExp, Université de Montpellier, INSERM, CNRS, Cardiology Department, CHU de Montpellier, France (F.R., M.A.).
  3. Cardiology Division, University Hospital of Mulhouse, Hôpital Emile Muller, Mulhouse, France (D.B.).
  4. Université de Poitiers, CIC Inserm 1402n CHU de Poitiers, France (C.B., B.A.).
  5. Cardiology Department CHRU de Tours and EA4245 T2i Tours University, France (F.I., D.A.).
  6. Centre Hospitalier Saint-Joseph Saint-Luc, Invasive Cardiology Department, Lyon, France (O.D.).
  7. Institut MITOVASC, CNRS 6015 INSERM U1083, Université d'Angers, Cardiology Division, CHU Angers, France (L.B., F.P.).
  8. Pharmacy Department, FRIPHARM-RC (C.D.), Hospices Civils de Lyon, France.
  9. UMR 5558 CNRS UCBL Biostatistics Departement (F.B., D.M.-B.), Hospices Civils de Lyon, France.
  10. INSERM CarMeN 1060, IRIS Team, Claude Bernard University, Lyon, France (F.B.).
  11. CREATIS CNRS 5220 INSERM U1206 Research Lab, Radiology Department, University Hospital/CHU Saint Etienne, France (P.C.).

PMID: 34420373 PMCID: PMC8462445 DOI: 10.1161/CIRCULATIONAHA.121.056177

Abstract

BACKGROUND: Inflammation is a key factor of myocardial damage in reperfused ST-segment-elevation myocardial infarction. We hypothesized that colchicine, a potent anti-inflammatory agent, may reduce infarct size (IS) and left ventricular (LV) remodeling at the acute phase of ST-segment-elevation myocardial infarction.

METHODS: In this double-blind multicenter trial, we randomly assigned patients admitted for a first episode of ST-segment-elevation myocardial infarction referred for primary percutaneous coronary intervention to receive oral colchicine (2-mg loading dose followed by 0.5 mg twice a day) or matching placebo from admission to day 5. The primary efficacy outcome was IS determined by cardiac magnetic resonance imaging at 5 days. The relative LV end-diastolic volume change at 3 months and IS at 3 months assessed by cardiac magnetic resonance imaging were among the secondary outcomes.

RESULTS: We enrolled 192 patients, 101 in the colchicine group and 91 in the control group. At 5 days, the gadolinium enhancement-defined IS did not differ between the colchicine and placebo groups with a mean of 26 interquartile range (IQR) [16-44] versus 28.4 IQR [14-40] g of LV mass, respectively (

CONCLUSIONS: In this randomized, placebo-controlled trial, oral administration of high-dose colchicine at the time of reperfusion and for 5 days did not reduce IS assessed by cardiac magnetic resonance imaging. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03156816.

Keywords: clinical trial; colchicine; heart injuries; inflammation; myocardial infarction; thrombosis; ventricular remodeling

References

  1. Eur Heart J. 2018 Jan 7;39(2):119-177 - PubMed
  2. J Am Coll Cardiol. 2014 Apr 29;63(16):1593-603 - PubMed
  3. J Am Coll Cardiol. 2004 Dec 21;44(12):2383-9 - PubMed
  4. Inflammation. 2016 Feb;39(1):182-189 - PubMed
  5. Eur Heart J. 2020 Nov 7;41(42):4092-4099 - PubMed
  6. J Cardiovasc Pharmacol. 1996 Jun;27(6):876-83 - PubMed
  7. Circulation. 2020 Nov 17;142(20):1890-1900 - PubMed
  8. J Am Coll Cardiol. 2021 Apr 20;77(15):1845-1855 - PubMed
  9. Cardiology. 2021;146(2):151-160 - PubMed
  10. Am J Med. 2006 Aug;119(8):707.e11-6 - PubMed
  11. Am Heart J. 2019 Sep;215:62-69 - PubMed
  12. Semin Arthritis Rheum. 2015 Dec;45(3):341-50 - PubMed
  13. Arthritis Res Ther. 2020 Feb 13;22(1):28 - PubMed
  14. N Engl J Med. 2019 Dec 26;381(26):2497-2505 - PubMed
  15. J Nucl Cardiol. 2018 Apr;25(2):572-580 - PubMed
  16. N Engl J Med. 2008 Jul 31;359(5):473-81 - PubMed
  17. J Thromb Thrombolysis. 2020 Aug;50(2):468-472 - PubMed
  18. Nat Rev Cardiol. 2014 May;11(5):255-65 - PubMed
  19. Circulation. 2020 Nov 17;142(20):1996-1998 - PubMed
  20. Circ Res. 2016 Jun 24;119(1):91-112 - PubMed
  21. Atherosclerosis. 2009 Nov;207(1):191-4 - PubMed
  22. J Thromb Thrombolysis. 2012 Jan;33(1):88-94 - PubMed
  23. Circ J. 2013;77(3):580-7 - PubMed
  24. Circulation. 2015 Oct 13;132(15):1395-403 - PubMed
  25. Arch Cardiovasc Dis. 2017 Jun - Jul;110(6-7):395-402 - PubMed
  26. Transl Res. 2016 Jan;167(1):152-66 - PubMed
  27. Fundam Clin Pharmacol. 1989;3(5):537-43 - PubMed
  28. Circulation. 2020 Nov 17;142(20):1901-1904 - PubMed
  29. PLoS One. 2021 Jan 28;16(1):e0245684 - PubMed
  30. PLoS One. 2017 Oct 12;12(10):e0186013 - PubMed
  31. J Am Coll Cardiol. 2010 Mar 23;55(12):1200-1205 - PubMed
  32. N Engl J Med. 2020 Nov 5;383(19):1838-1847 - PubMed
  33. J Cardiovasc Magn Reson. 2017 Mar 13;19(1):26 - PubMed
  34. JAMA Cardiol. 2018 Jul 1;3(7):642-649 - PubMed
  35. Radiology. 2011 Oct;261(1):116-26 - PubMed
  36. Clin Ther. 2014 Oct 1;36(10):1465-79 - PubMed
  37. Rheumatology (Oxford). 2006 Mar;45(3):274-82 - PubMed
  38. Arch Intern Med. 2004 Dec 13-27;164(22):2472-6 - PubMed
  39. Basic Res Cardiol. 2013 Nov;108(6):383 - PubMed

Publication Types